Business
Amarantus Announces Positive Pre-Clinical Data for MANF in Wolfram Syndrome Presented at the 79th Annual Scientific Sessions of the American Diabetes Association
Amarantus Announces Positive Pre-Clinical Data for MANF in Wolfram Syndrome Presented at the 79th Annual Scientific Sessions of the American Diabetes Association.
About this update from Amarantus Bioscience Holdings, Inc.
[{"type":"text","content":"\nNEW YORK, NY, June 18, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (the “Company,” or AMBS), a US-based JLABS-alumnus biotechnology holding company developing first-in-class orphan neurologic, regenerative medicine and ophthalmic therapies and diagnostics through its subsidiaries, today announced that positive results from in vitro and animal studies on MANF in the treatment of Wolfram Syndrome were presented at the 79th Annual Scientific Sessions of the American Diabetes Association.\n The abstract entitled ‘Mesencephalic Astrocyte-Derived Neurotrophic Factor (MANF): A New Therapeutic Target for Wolfram Syndrome,’ describes positive results that show MANF: Activates proliferation of beta cell in WFS1 genetic animal models of Wolfram Syndrome Suppresses key apoptosis and proteins misfolding Activates the pro-survival and pro-protein folding mTOR/S6K signaling pathway “MANF appears to have significant potential as a therapeutic agent for Wolfram Syndrome,” said Stephanie Gebel, Co-Founder and Chairman of the Board at the Snow Foundation, a co-sponsor of the research. “Going forward, we will be working with Amarantus to help bring this exciting research into clinical development to help the pediatric patients who are affected by Wolfram Syndrome.” About Wolfram Syndrome Wolfram Syndrome is considered a rare disease and afflicts about 1 in 500,000 people. There are approximately 30,000 patients in the world who have this disease. There are currently no drug therapies or cures that exist for Wolfram Syndrome. As a result, more than 60% of Wolfram patients die before age 30. It is expected that a treatment for Wolfram's Syndrome would fall under the rare pediatric disease designation (RPDD) regulatory pathway with the US FDA. Wolfram Syndrome is a condition that affects many of the body's systems.  It is a rare, monogenic disease caused by a mutation in the WFS1 gene. Typically, it first presents with juvenile onset type1 diabetes, often followed by optic nerve atrophy, hearing loss and cortical neurodegeneration. Wolfram syndrome is often fatal by mid-adulthood due to complications from the many features of the condition, such as health problems related to diabetes mellitus or neurological problems. MANF is an endoplasmi...